MMP-7 Antibody (Rabbit mAb) [G24L14]

CatNo: F3076

    Application: Reactivity:
    • Lane 1: Recombinant(GST) Rat MMP-7 Protein
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    キーポイント

    WB
    転写条件(ウェット): 200 mA, 60 min

    使用情報

    Dilution
    1:1000
    1:100
    Application
    WB, IHC, IP
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Mouse, Rat
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    30 kDa 28 kDa, 20-22 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。
    ポジティブコントロール Mouse small intestine; Rat prostate
    ネガティブコントロール Mouse colon

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 60 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
    IHC
    Experimental Protocol:
     
    Deparaffinization/Rehydration
    1. Deparaffinize/hydrate sections:
    2. Incubate sections in three washes of xylene for 5 min each.
    3. Incubate sections in two washes of 100% ethanol for 10 min each.
    4. Incubate sections in two washes of 95% ethanol for 10 min each.
    5. Wash sections two times in dH2O for 5 min each.
    6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
     
    Staining
    1. Wash sections in dH2O three times for 5 min each.
    2. Incubate sections in 3% hydrogen peroxide for 10 min.
    3. Wash sections in dH2O two times for 5 min each.
    4. Wash sections in wash buffer for 5 min.
    5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
    6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
    7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
    8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
    9. Wash sections three times with wash buffer for 5 min each.
    10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
    11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
    12. Immerse slides in dH2O.
    13. If desired, counterstain sections with hematoxylin.
    14. Wash sections in dH2O two times for 5 min each.
    15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
    16. Mount sections with coverslips and mounting medium.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    MMP-7 Antibody (Rabbit mAb) [G24L14] detects endogenous levels of total MMP-7 protein.
    タンパク質の局在
    細胞外マトリックス、細胞外環境
    Uniprot ID
    P09237
    Clone
    G24L14
    Synonym(s)
    MAT; Matrilysin; matrilysin, uterine; Matrin; matrix metallopeptidase 7; matrix metalloproteinase 7; Matrix metalloproteinase-7; MMP-7; Mmp7; Pump-1 protease; Uterine metalloproteinase
    Background
    MMP-7, also known as matrilysin, is a secreted zinc-dependent endopeptidase of the matrix metalloproteinase family characterized as a “minimal-domain” MMP that lacks the large hemopexin-like C-terminal domain yet efficiently cleaves a broad spectrum of extracellular matrix and non-matrix substrates, positioning it as a compact but versatile regulator of tissue remodeling and tumor biology. The protein is synthesized as a latent proenzyme containing an N‑terminal signal peptide, a prodomain that maintains catalytic zinc in an inactive configuration through the “cysteine switch,” and a catalytic domain with the conserved HEXGHXXGXXHS motif and binding sites for zinc and calcium ions; proteolytic removal of the prodomain generates active MMP-7, which can then degrade matrix components such as proteoglycans, fibronectin, laminin and elastin, facilitating basement membrane and stromal remodeling. MMP-7 extends its impact beyond ECM degradation by processing a range of non-ECM proteins that modulate growth, survival and invasion: it cleaves insulin-like growth factor binding proteins to increase IGF bioavailability and enhance proliferation, converts membrane-bound heparin-binding EGF precursor (proHB‑EGF) into mature HB‑EGF that stimulates EGFR signaling, and sheds cell-surface Fas ligand and TNF‑α precursors to soluble forms that influence apoptosis of neighboring cells within the tumor microenvironment. MMP-7 also cleaves E‑cadherin, generating soluble E‑cadherin fragments that weaken cell–cell adhesion and promote invasion, and participates in ectodomain shedding of other adhesion and signaling molecules, thereby coordinating structural and signaling changes that support tumor progression. In angiogenesis, recombinant MMP-7 directly accelerates proliferation of human umbilical vein endothelial cells in a dose-dependent manner on type I and IV collagen, and upregulates endothelial secretion of MMP‑1 and MMP‑2 without altering VEGF production, indicating that MMP-7 can act as a pro-angiogenic factor by amplifying the local protease milieu that drives basement membrane dissolution, endothelial migration and neovessel formation. Expression analyses across cancers show that MMP-7 is frequently overexpressed in epithelial tumors, including colorectal, gastric, lung, and prostate cancers, and its levels correlate with advanced stage, lymph node metastasis, and poor prognosis, leading to recognition of MMP-7 as an oncogenic effector that mediates proliferation, differentiation, metastasis and invasion via multiple mechanisms. In colorectal cancer, MMP-7 is secreted from cancer-induced neovessels and acts as a metastatic factor, while in lung adenocarcinoma, it is upregulated by COX‑2 and promotes proliferation and invasion of tumor cells, linking inflammatory COX‑2 signaling to protease-dependent invasive behavior. Beyond oncology, MMP-7 is implicated in kidney disease as a regulator of tubular and interstitial remodeling, and urinary MMP-7 is emerging as a sensitive biomarker of kidney injury, reflecting its role in ECM turnover and fibrosis. The minimal-domain metalloprotease structure, activation via prodomain removal, ability to cleave both ECM and key non-ECM regulators (IGFBPs, HB‑EGF, FasL, TNF‑α, E‑cadherin), and demonstrated roles in angiogenesis, tumor invasion, metastasis and organ injury make MMP-7 a mechanistically rich target for evaluating protease-driven remodeling in cancer, fibrosis, immune pathologies, and for exploring MMP-7 as a diagnostic and therapeutic node in disease-associated microenvironments.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください